| Literature DB >> 35093149 |
Martina Huemer1,2, Markus A Landolt3,4, Florin Bösch5,3,4, Nina A Zeltner5,3,4, Matthias R Baumgartner5.
Abstract
BACKGROUND: Acute intoxication-type inborn errors of metabolism (IT-IEM) such as urea cycle disorders and non-acute IT-IEM such as phenylketonuria (PKU) and their treatment have a major impact on the life of affected children and families. Yet patients' and parents' perspectives on the burdens of IT-IEM and its effects on everyday functioning and well-being have rarely been addressed. Patient- and observer-reported outcomes (PROs/ObsROs) are critically important to evaluate and target health care and treatment efficacy. Therefore, it is mandatory to define PROs/ObsROs relevant to patients with IT-IEM, their families, and health care professionals and to provide valid, standardised and reliable measuring instruments. To achieve consensus we performed a two-round, electronic-based modification of a Delphi survey including 27 parents of affected children, nine teenage patients and 35 health professionals (physicians, nutritionists, psychologists). The final set of PROs/ObsROs was discussed and defined in an online consensus meeting with a subsample of three health professionals, three parents and two patients. For this final set, appropriate measures (PROMs/ObsROMs) were assembled.Entities:
Keywords: Inborn errors of metabolism; Maple syrup urine disease; Organic acidurias; PROMs; PROs; Patient-reported outcome measures; Patient-reported outcomes; Phenylketonuria; Rare metabolic diseases; Urea cycle disorders
Mesh:
Year: 2022 PMID: 35093149 PMCID: PMC8800290 DOI: 10.1186/s13023-022-02183-2
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Fig. 1Flow chart of the modified Delphi process. In Survey two PROs were forwarded to the final consensus meeting, if they were rated as 7–9 by 70% or more of participants and as 1–3 by less than 15%. PROs were also forwarded, if they were rated as 7–9 by ≥ 90% of one stakeholder group, independently of the rating behavior of the other stakeholder group. PRO patient-reported outcome, HP health care providers, n sample size, IT-IEM intoxication-type inborn errors of metabolism
Characteristics of participants in the Delphi survey two
| HP (n = 30) | Patients (n = 9) | Parents (n = 24) | ||
|---|---|---|---|---|
| 11–18 years (14.8) | 1–19 years (9.7) | |||
| Physician | 16 (53.3%) | |||
| Nutritionist | 8 (26.7%) | Female | 3 (33.3%) | 12 (50%) |
| Psychologist | 6 (20%) | Male | 6 (66.7%) | 12 (50%) |
| Switzerland | 8 (26.7%) | PKU | 3 (33.3%) | 10 (41.7%) |
| Germany | 7 (23.4%) | OA | 2 (22.2%) | 9 (37.5%) |
| Austria | 6 (20%) | UCD | 4 (44.5%) | 4 (16.6%) |
| USA | 4 (13.3%) | MSUD | 0 | 1 (4.2%) |
| Italy | 4 (13.3%) | |||
| Netherlands | 1 (3.3%) | Switzerland | 7 (77.8%) | 18 (75%) |
| Austria | 2 (22.2%) | 6 (25%) | ||
| 3–5 years | 3 (10%) | |||
| > 5 years | 27 (90%) |
HP health care providers, n sample size, r range, m mean, USA United States of America, PKU phenylketonuria, OA organic acidurias, UCD urea cycle disorders, MSUD maple syrup urine disease
Fig. 2Results of survey two. The bars represent the percentage of participants rating the PRO as ‘very important’ (score 7–9) in survey 2. The dotted line marking 70% of “very important” rates represents the level of agreement for consensus to be included. Underlined PROs were included in the final core set after the final review in the consensus meeting. HP health care providers, PRO patient reported outcome, HrQoL health-related quality of life
Stakeholder ratings of the final core set of relevant PROs across the two Delphi surveys
| HP (median/IQR) | Patients and parents (median/IQR) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total sample (n = 30) | Total sample (n = 33) | Non-acute sample (n = 13) | Acute sample (n = 20) | |||||
| S1 | S2 | S1 | S2 | S1 | S2 | S1 | S2 | |
| Patients’ HrQoL | 9 (1) | 9 (1) | 9 (1) | 9 (1) | 9 (1) | 9 (1) | 9 (2.5) | 9 (0.5) |
| Positive affect | 7 (2) | 7 (2) | 8 (4) | 7.5 (2) | 8 (2.75) | 8.5 (2) | 8 (4) | 8 (2.5) |
| Stress | 7 (2) | 8 (1) | 8 (2.75) | 8 (1) | 8 (2.75) | 8 (2) | 8 (2) | 8 (2) |
| Physical activity | 7 (2.75) | 7 (1.75) | 8 (2) | 8 (1.75) | 8 (1.75) | 8 (2) | 8 (2) | 8 (1.5) |
| Peer relationships | 8 (1) | 8 (1.5) | 8 (2) | 8 (1.5) | 7 (1) | 9 (1.75) | 9 (1) | 8 (1.5) |
| Social participation | –a | 8 (1) | –a | 8 (1) | –a | 9 (0.75) | –a | 8 (3) |
| Cognitive functioning (behavioural) | 8 (2) | 8 (2) | 8 (2) | 8.5 (2) | 8.5 (2) | 9 (1) | 8 (2) | 9 (1) |
| Self-efficacy (towards the disease) | 8 (1) | 8 (1) | 9 (2) | 8 (1) | 9 (2.75) | 8 (1.75) | 8.5 (1.75) | 9 (1) |
| Patients' disease- and treatment knowledge | 8 (2) | 9 (1) | 9 (1) | 9 (1) | 9 (1) | 9 (2) | 9 (1.75) | 9 (0) |
| Patients’ attitude towards disease and treatment | 8 (2) | 9 (1) | 8.5 (2) | 9 (1) | 8 (1) | 9 (2) | 9 (2.75) | 9 (1) |
| Treatment- and diet adversities for patients | 8 (2) | 8 (1) | 9 (1) | 8 (2) | 9 (1) | 9 (3.75) | 8.5 (2.75) | 9 (1) |
| Patients' compliance with diet and treatment | 8 (2) | 9 (1) | 8.5 (2) | 9 (1) | 8.5 (1.75) | 8 (2) | 8.5 (2) | 9 (1) |
| Parental HrQoL | 7 (3) | 8 (2) | 8.5 (3) | 8 (2) | 7 (3.75) | 9 (1) | 9 (1.75) | 7 (3.5) |
| Social support of the family | 8 (2.75) | 8 (1) | 7 (4) | 8 (1) | 6 (2) | 8 (2) | 8 (3.5) | 7 (2.5) |
| Parental disease- and treatment knowledge | 9 (1) | 9 (1) | 9 (1) | 9 (1) | 8.5 (1.75) | 9 (0) | 9 (0.75) | 9 (1) |
| Parental attitude towards disease and treatment | 9 (1) | 9 (0) | 9 (1) | 9 (0) | 9 (2) | 6.5 (0.75) | 9 (1) | 7 (0) |
| Parental stress | 8 (2) | 8 (2) | 7.5 (3.75) | 8 (2) | 6.5 (2.75) | 8 (2.75) | 8 (7) | 8 (2) |
Median and IQR for stakeholder ratings (9-point Likert scale; 1 = not at all important, 9 = very important) in the two consecutive survey rounds
HP health care providers, IQR interquartile range, n sample size, S1 survey one, S2 survey two, HrQoL health related quality of life
aPRO suggested by a participant during survey one